Antiviral therapy using ovine or bovine interferon-tau

• US 5,942,223 A
• Filed: 05/31/1995
• Issued: 08/24/1999
• Est. Priority Date: 03/02/1989
• Status: Expired due to Fees

• Current Assignee: University of Florida (State University System of Florida), The Women's Research Institute
• Original Assignee: University of Florida (State University System of Florida)
• Inventors: Bazer, Fuller Warren, Ott, Troy Lee, Heeke, Gino Van, Johnson, Howard Marcellus, Pontzer, Carol Hanlon
• Primary Examiner(s): Fitzgerald, David L.
• Application Number:
  US08/455,524
• Time in Patent Office: 1,546 Days
• Field of Search: 424/85.4, 424/85.7, 435/69.51
• US Class Current: 424/85.4
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: C07K 14/555 Interferons [IFN]
• CPC Class Codes: C07K 14/56 IFN-alpha
• CPC Class Codes: C07K 16/249 Interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence

Abstract

The invention provides antiviral therapeutic methods employing bovine or ovine interferon-tau (IFN-τ) proteins and polypeptides. The IFN-τ proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-τ has essentially no cytotoxic effects on treated cells as does, for example, IFN-α.

Claims

1. A method of inhibiting viral replication in cells of a subject infected with a virus, comprising

administering ovine or bovine interferon-tau to the subject in an amount effective to inhibit viral replication within said cells and which induces a chance in white blood cell count in the subject which is less than the change in white blood cell count which would be induced in the subject by an amount of interferon-alpha having the same viral inhibition effect.

2. The method of claim 1, where said virus is an RNA virus.

3. The method of claim 2, where said virus is selected from the group consisting of feline leukemia virus, ovine lentivirus, equine infectious anemia virus, bovine immunodeficiency virus, visna-maedi virus, and caprine arthritis encephalitis.

4. The method of claim 1, where said virus is a DNA virus.

5. The method of claim 1, wherein said virus is human immunodeficiency virus (HIV).

6. The method of claim 1, wherein said virus is hepatitis-B virus.

7. The method of claim 1, wherein said virus is hepatitis-C virus.

8. The method of claim 1, where said interferon-tau has the amino acid sequence presented as SEQ ID NO:

2.